Jazz Pharmaceuticals is now committing $935 million to add this prospect to its pipeline. The drug, dordaviprone, was developed by Durham, North Carolina-based Chimerix. The cancer is H3 K27M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback